Selective Akt inhibitors synergize with tyrosine kinase inhibitors and effectively override stroma-associated cytoprotection of mutant FLT3-positive AML cells - Wikidata - awgldk - TriplyDB

Selective Akt inhibitors synergize with tyrosine kinase inhibitors and effectively override stroma-associated cytoprotection of mutant FLT3-positive AML cells

Selective Akt inhibitors synergize with tyrosine kinase inhibitors and effectively override stroma-associated cytoprotection of mutant FLT3-positive AML cells

http://www.wikidata.org/entity/Q28486435

about

Systematic Quality Control Analysis of LINCS Data Microenvironmental regulation of therapeutic response in cancer Small molecule inhibitors in acute myeloid leukemia: from the bench to the clinic A-770041 reverses paclitaxel and doxorubicin resistance in osteosarcoma cells.NVP-TAE684 reverses multidrug resistance (MDR) in human osteosarcoma by inhibiting P-glycoprotein (PGP1) function.The Bone Marrow-Mediated Protection of Myeloproliferative Neoplastic Cells to Vorinostat and Ruxolitinib Relies on the Activation of JNK and PI3K Signalling Pathways.Identification of Existing Drugs That Effectively Target NTRK1 and ROS1 Rearrangements in Lung Cancer.Modeling selective elimination of quiescent cancer cells from bone marrow.Targeted drug discovery for pediatric leukemia.The evolving role of FLT3 inhibitors in acute myeloid leukemia: quizartinib and beyond.Targeting PI3K/AKT/mTOR network for treatment of leukemia.Novel approaches to pediatric leukemia treatment.Novel drug therapies in myeloid leukemia.FLT3 Inhibitors in Acute Myeloid Leukemia: Current Status and Future Directions.FLT3-ITD confers resistance to the PI3K/Akt pathway inhibitors by protecting the mTOR/4EBP1/Mcl-1 pathway through STAT5 activation in acute myeloid leukemia The Role of the Central Nervous System Microenvironment in Pediatric Acute Lymphoblastic Leukemia.Midostaurin: a novel therapeutic agent for patients with FLT3-mutated acute myeloid leukemia and systemic mastocytosis.A Facile, In Vitro 384-Well Plate System to Model Disseminated Tumor Cells in the Bone Marrow Microenvironment.Persistent DNA strand breaks induce a CAF-like phenotype in normal fibroblasts.

P2860

Q28818488-9BE87901-E52C-41D2-AB47-0CA12B3F54FC Q33654609-76FD9E60-C4F6-4687-A3B0-937F456551A7 Q34817365-8BB42AC7-31C5-4909-B3C9-9CC916DF6B55 Q35263202-CE3964E6-1B30-49C0-8A73-22959BDEAFFB Q35851832-32F14C44-3296-4EE0-8386-7EF1FE8A4AB8 Q35856790-7F4C70FD-7320-48AC-920C-12114A4E197F Q36066539-604E2AA9-BD27-4E3F-9D26-EDC69C54B032 Q36360112-397444B9-35F1-4710-8944-5BD13CCA1E32 Q36989223-66ABC81B-E4F4-442E-AF77-5FB15CA30FA6 Q38216649-8B30CC9F-C392-4A7B-9573-CA5FA21D792D Q38364871-DDB6692A-1D18-4022-9267-443E6B6A2E73 Q38500371-12E197ED-1B8E-46E9-9C35-952E2A80B614 Q38510486-1F9CF6BE-2EBD-40CD-9CE9-C5347FE943BC Q38675400-6B6ABE3E-90FD-4CAB-B2F7-968234BCB80E Q38892684-A7484C91-6C63-4746-9F37-9903C42DC227 Q39297348-60962D63-67E8-4E86-AC83-387EBEC03A70 Q42376734-1E9D8828-31B2-40B1-A081-8F1AF15AD38D Q47445458-7AD9BC9E-93E7-473C-83FB-0279CCA550FF Q55078362-2519ABCF-7B0D-4D5A-B5AD-E44B4194B243

P2860

Selective Akt inhibitors synergize with tyrosine kinase inhibitors and effectively override stroma-associated cytoprotection of mutant FLT3-positive AML cells

http://www.wikidata.org/entity/Q28486435

description

2013 nî lūn-bûn

@nan

2013 թուականին հրատարակուած գիտական յօդուած

@hyw

2013 թվականին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年学术文章

@wuu

2013年学术文章

@zh-cn

2013年学术文章

@zh-hans

2013年学术文章

@zh-my

2013年学术文章

@zh-sg

2013年學術文章

@yue

name

Selective Akt inhibitors syner ...... mutant FLT3-positive AML cells

@ast

Selective Akt inhibitors syner ...... mutant FLT3-positive AML cells

@en

Selective Akt inhibitors syner ...... mutant FLT3-positive AML cells

@nl

type

label

Selective Akt inhibitors syner ...... mutant FLT3-positive AML cells

@ast

Selective Akt inhibitors syner ...... mutant FLT3-positive AML cells

@en

Selective Akt inhibitors syner ...... mutant FLT3-positive AML cells

@nl

prefLabel

Selective Akt inhibitors syner ...... mutant FLT3-positive AML cells

@ast

Selective Akt inhibitors syner ...... mutant FLT3-positive AML cells

@en

Selective Akt inhibitors syner ...... mutant FLT3-positive AML cells

@nl

P1433

Q28486435-3F9539AA-26E7-4C07-994A-E2DC23CD0EAF

P1476

Q28486435-0499AB56-9BE7-4BDC-B3EA-722FA9A52CA5

P2093

Q28486435-067B87B8-C2C9-45AE-8859-5815E4A752D8

Q28486435-13AD3C50-B154-4CD4-92EA-814EE51FB0BC

Q28486435-24046B5C-A958-4D8C-92B9-F9B76EFEDD93

Q28486435-2A8FA786-3857-49DB-9B8B-DD011DC689CB

Q28486435-43BD6ACE-BFEB-4AA0-8138-A60B2E6D734F

Q28486435-43F55435-BFED-458C-89B3-CCCC0AC63DEA

Q28486435-5F4D502E-435E-46FC-9F40-F3F884A11138

Q28486435-6258CB7E-02E4-4C77-B4F9-6AF85F66DFDD

Q28486435-6F1624D5-FAB4-4754-84AC-8F3919C564A3

Q28486435-7CFC1945-4D3D-4474-B76D-2638430C58AA

P2860

Q28486435-04D5C42F-8778-459F-8AF6-A0C4AFFF19DF

Q28486435-0E862985-C8F1-47F2-85F5-95F3A3E97AA7

Q28486435-101A4760-226A-4AE4-85DA-01BC07979345

Q28486435-134B612D-CA19-44A4-98C8-8FA2B932F181

Q28486435-18DE69D1-21AC-413B-A9BA-09F070D5E305

Q28486435-23A53BD9-08A6-43D9-B01F-85190E8EEA37

Q28486435-2DC6F871-48CB-435F-89F0-13DBF45B5E46

Q28486435-33D03F56-3650-4DC3-826B-21247B74D1EC

Q28486435-367551E7-3438-451C-9741-32C7244089B6

Q28486435-3C3D52C9-6A90-45DD-BB1D-489977FC8A0C

P304

Q28486435-5D84FC16-4B42-48EE-A7AB-3BDA1DFA2C4D

P31

Q28486435-6A7B88B6-400F-4351-BBBE-EEFB721F3F08

P356

Q28486435-986607A4-6EA7-415D-82FA-22E41CFF970D

P407

Q28486435-37DBBBAC-0C41-4CB0-B26F-79DE9E2BC10A

P433

Q28486435-0857D161-EB35-483C-9132-1A86A9EFE924

P478

Q28486435-FC38C76B-9CCB-446F-8047-13434754B021

P50

Q28486435-32BF864E-C205-4409-8859-721A17A9FCC8

P577

Q28486435-0FBA4225-2252-4C54-8C90-F0C9057425CF

P5875

Q28486435-8EEC0CBC-C3EA-4605-92F8-0EFA5ED89E70

P698

Q28486435-9AA1BA8B-3EF2-41CE-93EE-A44614912B5F

P932

Q28486435-2A61323F-0642-4EAE-A3B5-1C0C9CD3B70B

P356

JOURNAL.PONE.0056473

P1433

P1476

Selective Akt inhibitors syner ...... mutant FLT3-positive AML cells

@en

P2093

Atsushi Nonami

http://www.w3.org/2001/XMLSchema#string

Constantine Mitsiades

http://www.w3.org/2001/XMLSchema#string

Ellen Weisberg

http://www.w3.org/2001/XMLSchema#string

Erik Nelson

http://www.w3.org/2001/XMLSchema#string

Feiyang Liu

http://www.w3.org/2001/XMLSchema#string

Ilene Galinsky

http://www.w3.org/2001/XMLSchema#string

James D Griffin

http://www.w3.org/2001/XMLSchema#string

Jianming Zhang

http://www.w3.org/2001/XMLSchema#string

Maria Nicolais

http://www.w3.org/2001/XMLSchema#string

Martin Sattler

http://www.w3.org/2001/XMLSchema#string

P2860

The role of FLT3 in haematopoietic malignancies

Survey of activated FLT3 signaling in leukemia

Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors

Smac mimetics: implications for enhancement of targeted therapies in leukemia

Using combination therapy to override stromal-mediated chemoresistance in mutant FLT3-positive AML: synergism between FLT3 inhibitors, dasatinib/multi-targeted inhibitors and JAK inhibitors.

Inhibition of CXCR4 in CML cells disrupts their interaction with the bone marrow microenvironment and sensitizes them to nilotinib

Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412.

Environment-mediated drug resistance in Bcr/Abl-positive acute lymphoblastic leukemia

Potentiation of antileukemic therapies by the dual PI3K/PDK-1 inhibitor, BAG956: effects on BCR-ABL- and mutant FLT3-expressing cells.

Bone marrow adherent layers inhibit apoptosis of acute myeloid leukemia cells.

P304

e56473

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1371/JOURNAL.PONE.0056473

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

8

http://www.w3.org/2001/XMLSchema#string

P50

P577

2013-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

235718417

http://www.w3.org/2001/XMLSchema#string

P698

23437141

http://www.w3.org/2001/XMLSchema#string

P932

3578845

http://www.w3.org/2001/XMLSchema#string